Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1....

Full description

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 371; no. 6534; pp. 1152 - 1153
Main Authors Muik, Alexander, Wallisch, Ann-Kathrin, Sänger, Bianca, Swanson, Kena A., Mühl, Julia, Chen, Wei, Cai, Hui, Maurus, Daniel, Sarkar, Ritu, Türeci, Özlem, Dormitzer, Philip R., Şahin, Uğur
Format Journal Article
LanguageEnglish
Published United States The American Association for the Advancement of Science 12.03.2021
American Association for the Advancement of Science
Subjects
Online AccessGet full text
ISSN0036-8075
1095-9203
1095-9203
DOI10.1126/science.abg6105

Cover

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al. ). Serum was derived from 40 subjects in two age groups 21 days after the booster shot. The vaccine remained effective against B.1.1.7 with a slight but significant decrease in neutralization that was more apparent in participants under 55 years of age. Thus, the vaccine provides a significant “cushion” of protection against this variant. Science , this issue p. 1152 ; see also p. 1103 Despite the many genetic changes in the B.1.1.7 (VOC 202012/01) 2020 UK variant of SARS-CoV-2, the BioNTech-Pfizer mRNA vaccine remains protective. Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA–based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
AbstractList Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA-based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al.). Serum was derived from 40 subjects in two age groups 21 days after the booster shot. The vaccine remained effective against B.1.1.7 with a slight but significant decrease in neutralization that was more apparent in participants under 55 years of age. Thus, the vaccine provides a significant “cushion” of protection against this variant. Science, this issue p. 1152; see also p. 1103 Despite the many genetic changes in the B.1.1.7 (VOC 202012/01) 2020 UK variant of SARS-CoV-2, the BioNTech-Pfizer mRNA vaccine remains protective. Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA–based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA-based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA-based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
Vaccine protects against B1.1.7 variantThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al.). Serum was derived from 40 subjects in two age groups 21 days after the booster shot. The vaccine remained effective against B.1.1.7 with a slight but significant decrease in neutralization that was more apparent in participants under 55 years of age. Thus, the vaccine provides a significant “cushion” of protection against this variant.Science, this issue p. 1152; see also p. 1103Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA–based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al. ). Serum was derived from 40 subjects in two age groups 21 days after the booster shot. The vaccine remained effective against B.1.1.7 with a slight but significant decrease in neutralization that was more apparent in participants under 55 years of age. Thus, the vaccine provides a significant “cushion” of protection against this variant. Science , this issue p. 1152 ; see also p. 1103 Despite the many genetic changes in the B.1.1.7 (VOC 202012/01) 2020 UK variant of SARS-CoV-2, the BioNTech-Pfizer mRNA vaccine remains protective. Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the messenger RNA–based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
Author Wallisch, Ann-Kathrin
Chen, Wei
Sarkar, Ritu
Muik, Alexander
Maurus, Daniel
Türeci, Özlem
Dormitzer, Philip R.
Mühl, Julia
Sänger, Bianca
Şahin, Uğur
Swanson, Kena A.
Cai, Hui
Author_xml – sequence: 1
  givenname: Alexander
  orcidid: 0000-0003-4561-2273
  surname: Muik
  fullname: Muik, Alexander
  organization: BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
– sequence: 2
  givenname: Ann-Kathrin
  orcidid: 0000-0001-5450-3218
  surname: Wallisch
  fullname: Wallisch, Ann-Kathrin
  organization: BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
– sequence: 3
  givenname: Bianca
  orcidid: 0000-0002-4030-2500
  surname: Sänger
  fullname: Sänger, Bianca
  organization: BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
– sequence: 4
  givenname: Kena A.
  orcidid: 0000-0002-3389-8414
  surname: Swanson
  fullname: Swanson, Kena A.
  organization: Pfizer, 401 N. Middletown Rd., Pearl River, NY 10960, USA
– sequence: 5
  givenname: Julia
  orcidid: 0000-0002-2222-3227
  surname: Mühl
  fullname: Mühl, Julia
  organization: BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
– sequence: 6
  givenname: Wei
  surname: Chen
  fullname: Chen, Wei
  organization: Pfizer, 401 N. Middletown Rd., Pearl River, NY 10960, USA
– sequence: 7
  givenname: Hui
  surname: Cai
  fullname: Cai, Hui
  organization: Pfizer, 401 N. Middletown Rd., Pearl River, NY 10960, USA
– sequence: 8
  givenname: Daniel
  orcidid: 0000-0003-2989-264X
  surname: Maurus
  fullname: Maurus, Daniel
  organization: BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
– sequence: 9
  givenname: Ritu
  surname: Sarkar
  fullname: Sarkar, Ritu
  organization: Pfizer, 401 N. Middletown Rd., Pearl River, NY 10960, USA
– sequence: 10
  givenname: Özlem
  orcidid: 0000-0002-0623-1497
  surname: Türeci
  fullname: Türeci, Özlem
  organization: BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
– sequence: 11
  givenname: Philip R.
  orcidid: 0000-0003-0671-6360
  surname: Dormitzer
  fullname: Dormitzer, Philip R.
  organization: Pfizer, 401 N. Middletown Rd., Pearl River, NY 10960, USA
– sequence: 12
  givenname: Uğur
  orcidid: 0000-0003-0363-1564
  surname: Şahin
  fullname: Şahin, Uğur
  organization: BioNTech, An der Goldgrube 12, 55131 Mainz, Germany., TRON gGmbH – Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Freiligrathstraße 12, 55131 Mainz, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33514629$$D View this record in MEDLINE/PubMed
BookMark eNp1kU9rVDEUxYNU7LS6dicBN27eNH8mLy8boR2sCqWCrW5DknczTXmTjMl7A3Xld-g39JOY2qloQbLI4v7O4Z57DtBeTBEQeknJnFLWHhUXIDqYG7tqKRFP0IwSJRrFCN9DM0J423REin10UMo1IXWm-DO0z7mgi5apGbLnMI3ZDOG7GUOKOHl8cfz5olmmrw3DQ4hgVoBP5rQ-iTcFpj5tQ54Ktjf45PyStswyvDXOVfTnj1sYggsj9PhqWpuIC2TzHD31ZijwYvcfoi-n7y6XH5qzT-8_Lo_PGieoGBvXt5QL6RUwAr2yhjPoCWl78MQLpqS1XBLa-95T17XcEq-YlVyqbmFbv-CH6O2972aya-gdxLtgepPD2uQbnUzQ_05iuNKrtNVSSSolrQZvdgY5fZugjHodioNhMBHSVDRbdLyjjKuuoq8foddpyrHG00wQIkSNQir16u-N_qzycP4KiHvA5VRKBq_r8X4XURcMg6ZE39WsdzXrXc1Vd_RI92D9P8UvHUitFg
CitedBy_id crossref_primary_10_1016_j_ebiom_2021_103762
crossref_primary_10_1038_s41467_021_25479_6
crossref_primary_10_1007_s12033_021_00353_4
crossref_primary_10_1016_j_cell_2021_03_036
crossref_primary_10_1038_s41598_023_48929_1
crossref_primary_10_1093_ofid_ofad431
crossref_primary_10_1016_j_jtbi_2022_111105
crossref_primary_10_1016_j_meegid_2021_104869
crossref_primary_10_1128_JVI_00404_21
crossref_primary_10_1021_acsanm_3c02880
crossref_primary_10_1016_j_celrep_2021_109415
crossref_primary_10_1001_jamanetworkopen_2021_47042
crossref_primary_10_1016_j_xcrm_2021_100405
crossref_primary_10_1007_s00508_021_01835_w
crossref_primary_10_1056_NEJMoa2110345
crossref_primary_10_1038_s41591_021_01318_5
crossref_primary_10_1021_acsinfecdis_2c00204
crossref_primary_10_1038_s42003_023_04589_5
crossref_primary_10_3390_molecules29235564
crossref_primary_10_1016_S2468_2667_21_00055_4
crossref_primary_10_1007_s12275_021_1348_5
crossref_primary_10_1515_mr_2021_0035
crossref_primary_10_1016_j_isci_2023_106562
crossref_primary_10_1016_j_ejmech_2023_115908
crossref_primary_10_3389_fimmu_2021_771011
crossref_primary_10_1016_j_chom_2021_03_002
crossref_primary_10_1128_mBio_00696_21
crossref_primary_10_1007_s13167_021_00267_w
crossref_primary_10_3390_v13122391
crossref_primary_10_1002_jmv_27425
crossref_primary_10_1128_JVI_00966_21
crossref_primary_10_1208_s12249_021_02058_y
crossref_primary_10_1002_jmv_29160
crossref_primary_10_3389_fimmu_2021_654165
crossref_primary_10_3390_v13101911
crossref_primary_10_3390_v13081421
crossref_primary_10_1038_s41392_021_00733_x
crossref_primary_10_1186_s12916_021_02149_4
crossref_primary_10_1016_j_cell_2021_03_013
crossref_primary_10_1007_s11356_021_16415_8
crossref_primary_10_3389_fimmu_2021_809244
crossref_primary_10_1136_postgradmedj_2021_140685
crossref_primary_10_1186_s12985_021_01633_w
crossref_primary_10_3389_fitd_2022_988665
crossref_primary_10_3390_v13071192
crossref_primary_10_1080_14737159_2021_1917998
crossref_primary_10_1038_s41467_021_25167_5
crossref_primary_10_1017_S0950268821002430
crossref_primary_10_1515_mr_2021_0021
crossref_primary_10_1002_ange_202110702
crossref_primary_10_1080_14760584_2021_1903879
crossref_primary_10_2139_ssrn_4114061
crossref_primary_10_3390_vaccines9060639
crossref_primary_10_1002_jmv_27310
crossref_primary_10_1111_joim_13372
crossref_primary_10_3390_jcm11071822
crossref_primary_10_1002_admt_202200387
crossref_primary_10_1016_j_apsb_2021_07_026
crossref_primary_10_1016_j_jcvp_2021_100016
crossref_primary_10_3390_vaccines12111238
crossref_primary_10_1016_S0140_6736_21_00947_8
crossref_primary_10_1093_infdis_jiab083
crossref_primary_10_3934_mbe_2022350
crossref_primary_10_1016_j_vaccine_2021_08_081
crossref_primary_10_1126_sciimmunol_ade9888
crossref_primary_10_3389_fimmu_2022_842468
crossref_primary_10_3390_ph14080751
crossref_primary_10_1002_rmv_2277
crossref_primary_10_1128_mSystems_00353_21
crossref_primary_10_1016_j_chom_2021_11_004
crossref_primary_10_3389_fimmu_2022_952229
crossref_primary_10_1016_j_ymthe_2023_02_012
crossref_primary_10_1128_mBio_02510_21
crossref_primary_10_1016_j_micpath_2022_105619
crossref_primary_10_1038_s41467_022_32665_7
crossref_primary_10_1007_s00705_021_05295_5
crossref_primary_10_1016_j_vaccine_2023_03_035
crossref_primary_10_1093_ajcp_aqab186
crossref_primary_10_1002_mef2_90
crossref_primary_10_1016_j_jbc_2022_101658
crossref_primary_10_3390_vaccines10091538
crossref_primary_10_3390_diseases10040112
crossref_primary_10_1146_annurev_med_042420_112725
crossref_primary_10_1128_jvi_01157_23
crossref_primary_10_3390_vaccines9070779
crossref_primary_10_3390_genes13122412
crossref_primary_10_1021_acsnano_1c01845
crossref_primary_10_1016_j_genrep_2021_101342
crossref_primary_10_1016_j_jconrel_2022_08_009
crossref_primary_10_3390_vaccines9101207
crossref_primary_10_1080_17576180_2024_2411920
crossref_primary_10_1080_21645515_2023_2273155
crossref_primary_10_3389_fcimb_2021_781429
crossref_primary_10_1016_j_imu_2021_100768
crossref_primary_10_3389_fmed_2022_849217
crossref_primary_10_1002_phar_2622
crossref_primary_10_1186_s13073_022_01098_8
crossref_primary_10_1002_anie_202110702
crossref_primary_10_3390_ijms241914622
crossref_primary_10_3390_pathogens10040429
crossref_primary_10_1016_j_cell_2023_09_022
crossref_primary_10_1038_s41421_021_00340_8
crossref_primary_10_1111_tme_12868
crossref_primary_10_1021_acsnano_3c08323
crossref_primary_10_1038_s41541_024_00815_1
crossref_primary_10_3390_vaccines10060874
crossref_primary_10_7554_eLife_72619
crossref_primary_10_1016_j_ijbiomac_2024_129284
crossref_primary_10_1038_s41598_021_99401_x
crossref_primary_10_1016_j_cell_2021_05_005
crossref_primary_10_1038_s41541_021_00389_2
crossref_primary_10_1016_j_meegid_2021_105191
crossref_primary_10_1007_s40199_022_00446_8
crossref_primary_10_1080_21645515_2022_2057161
crossref_primary_10_1016_j_celrep_2021_110167
crossref_primary_10_1016_j_micpath_2021_105161
crossref_primary_10_1080_21645515_2023_2174755
crossref_primary_10_1111_sji_13345
crossref_primary_10_3390_v13040638
crossref_primary_10_34084_bshr_1200144
crossref_primary_10_1093_cid_ciab555
crossref_primary_10_1098_rsfs_2021_0008
crossref_primary_10_3390_ijerph19020689
crossref_primary_10_3390_ijms23042172
crossref_primary_10_3390_v13040633
crossref_primary_10_1016_j_intimp_2023_109968
crossref_primary_10_1038_s41392_022_00874_7
crossref_primary_10_1186_s42269_022_00787_z
crossref_primary_10_1021_acssensors_3c02734
crossref_primary_10_1002_jmv_26924
crossref_primary_10_2174_1871526522666220818124416
crossref_primary_10_1126_science_abg4493
crossref_primary_10_1038_s41467_021_26401_w
crossref_primary_10_1093_clinchem_hvac081
crossref_primary_10_3390_ijms23084376
crossref_primary_10_1177_15353702211014146
crossref_primary_10_1016_j_anrea_2021_04_006
crossref_primary_10_1126_science_abg7404
crossref_primary_10_3390_vaccines10101655
crossref_primary_10_1093_oxfimm_iqab005
crossref_primary_10_1007_s11468_022_01754_0
crossref_primary_10_1111_1462_2920_15549
crossref_primary_10_3389_fvets_2022_1085613
crossref_primary_10_1126_sciadv_abo4100
crossref_primary_10_1038_s41598_022_04950_4
crossref_primary_10_4103_ijmr_ijmr_2544_21
crossref_primary_10_1016_j_heliyon_2023_e16750
crossref_primary_10_1016_j_accpm_2021_100848
crossref_primary_10_3390_biomedicines9101303
crossref_primary_10_1016_j_cell_2022_01_001
crossref_primary_10_1016_j_ebiom_2021_103544
crossref_primary_10_1038_s41591_021_01449_9
crossref_primary_10_1016_j_trsl_2021_11_007
crossref_primary_10_1128_JCM_00859_21
crossref_primary_10_3390_medicina59030507
crossref_primary_10_1016_j_biomaterials_2022_121460
crossref_primary_10_1038_s41577_021_00592_1
crossref_primary_10_2174_0929867328666210902094254
crossref_primary_10_1093_ofid_ofac124
crossref_primary_10_1172_jci_insight_155789
crossref_primary_10_3389_fimmu_2022_990071
crossref_primary_10_1172_JCI149335
crossref_primary_10_1016_j_cell_2022_06_023
crossref_primary_10_1002_jmv_28563
crossref_primary_10_2174_1381612828666220506142117
crossref_primary_10_1371_journal_pone_0257464
crossref_primary_10_1128_jcm_00178_22
crossref_primary_10_3389_fmicb_2023_1199561
crossref_primary_10_1038_s41467_022_34439_7
crossref_primary_10_1134_S2079086421070069
crossref_primary_10_3389_fcimb_2021_690621
crossref_primary_10_1002_adfm_202401983
crossref_primary_10_1038_s41467_022_31556_1
crossref_primary_10_1016_j_ajpath_2021_07_002
crossref_primary_10_1002_jmv_27487
crossref_primary_10_1080_21645515_2022_2105611
crossref_primary_10_1038_s41541_021_00404_6
crossref_primary_10_1016_j_biopha_2021_112176
crossref_primary_10_1093_ofid_ofab143
crossref_primary_10_1126_science_abn7591
crossref_primary_10_1038_s41392_021_00796_w
crossref_primary_10_1016_j_cell_2021_11_026
crossref_primary_10_3390_pathogens11020275
crossref_primary_10_1016_j_epidem_2022_100578
crossref_primary_10_1016_j_jconrel_2021_03_043
crossref_primary_10_21833_ijaas_2024_06_023
crossref_primary_10_1016_j_cell_2021_05_031
crossref_primary_10_1021_acs_analchem_4c01607
crossref_primary_10_3390_vaccines9040390
crossref_primary_10_3389_fmed_2021_806641
crossref_primary_10_3201_eid2711_211190
crossref_primary_10_1016_j_accpm_2021_100867
crossref_primary_10_3390_ijms23031646
crossref_primary_10_7759_cureus_28066
crossref_primary_10_7554_eLife_78633
crossref_primary_10_3390_vaccines9111211
crossref_primary_10_1016_j_str_2024_06_012
crossref_primary_10_1016_j_ebiom_2021_103805
crossref_primary_10_3390_v13071211
crossref_primary_10_1016_j_virol_2022_05_003
crossref_primary_10_3390_pathogens10060633
crossref_primary_10_1371_journal_pone_0257646
crossref_primary_10_1038_s41392_021_00644_x
crossref_primary_10_3390_vaccines10081251
crossref_primary_10_1016_j_smim_2021_101533
crossref_primary_10_1039_D2SC06665C
crossref_primary_10_1016_j_cell_2023_04_007
crossref_primary_10_1038_s41586_021_03412_7
crossref_primary_10_3390_vaccines10030349
crossref_primary_10_1186_s40779_021_00360_1
crossref_primary_10_1016_j_celrep_2024_114567
crossref_primary_10_1016_j_cell_2022_03_044
crossref_primary_10_1016_S2213_2600_21_00407_0
crossref_primary_10_1001_jama_2021_7563
crossref_primary_10_1056_NEJMoa2102214
crossref_primary_10_1126_science_abf4896
crossref_primary_10_1126_sciimmunol_abm3131
crossref_primary_10_14348_molcells_2021_0075
crossref_primary_10_3389_fimmu_2022_861050
crossref_primary_10_1038_s41586_021_03398_2
crossref_primary_10_1038_s41467_022_29477_0
crossref_primary_10_3389_fmed_2022_820544
crossref_primary_10_1016_j_jinf_2021_07_019
crossref_primary_10_1038_s41421_021_00282_1
crossref_primary_10_1038_s41576_021_00408_x
crossref_primary_10_1016_j_ajpath_2021_03_004
crossref_primary_10_1016_S1473_3099_21_00290_5
crossref_primary_10_3389_fimmu_2022_801522
crossref_primary_10_3390_v13071347
crossref_primary_10_1128_jvi_01578_21
crossref_primary_10_3390_vaccines11030682
crossref_primary_10_1016_j_mayocp_2021_08_013
crossref_primary_10_1038_s41586_021_03653_6
crossref_primary_10_3201_eid2708_210887
crossref_primary_10_1016_j_accpm_2021_100874
crossref_primary_10_1186_s41256_022_00245_3
crossref_primary_10_1371_journal_pone_0261229
crossref_primary_10_3390_ijms23062928
crossref_primary_10_1111_imr_13091
crossref_primary_10_1126_sciadv_abj6538
crossref_primary_10_1016_j_celrep_2023_112888
crossref_primary_10_1073_pnas_2102957118
crossref_primary_10_3390_microorganisms9081744
crossref_primary_10_1093_intimm_dxab061
crossref_primary_10_1016_j_isci_2022_103934
crossref_primary_10_1016_j_celrep_2021_109838
crossref_primary_10_1007_s11684_023_1034_6
crossref_primary_10_1111_jfbc_14354
crossref_primary_10_4049_jimmunol_2001287
crossref_primary_10_1016_j_jgg_2021_03_001
crossref_primary_10_1016_j_clim_2022_108999
crossref_primary_10_1038_s41421_022_00509_9
crossref_primary_10_1128_spectrum_03789_22
crossref_primary_10_2139_ssrn_3924614
crossref_primary_10_1126_sciimmunol_ade2283
crossref_primary_10_1016_j_celrep_2021_109385
crossref_primary_10_1126_sciadv_abl7682
crossref_primary_10_3389_fimmu_2022_816220
crossref_primary_10_1016_j_lanwpc_2022_100586
crossref_primary_10_51585_gjm_2021_2_0006
crossref_primary_10_3389_fimmu_2024_1259788
crossref_primary_10_1016_j_ijbiomac_2021_11_020
crossref_primary_10_1126_science_abh1766
crossref_primary_10_1038_s41467_021_24326_y
crossref_primary_10_1038_s41467_022_30163_4
crossref_primary_10_1038_s41421_021_00315_9
crossref_primary_10_1002_14651858_CD013825_pub2
crossref_primary_10_3389_fimmu_2021_730766
crossref_primary_10_3389_fpubh_2021_730611
crossref_primary_10_1186_s43168_021_00090_x
crossref_primary_10_3389_fimmu_2021_744242
crossref_primary_10_3390_v14050956
crossref_primary_10_1016_j_xcrm_2021_100355
crossref_primary_10_3390_cells10061434
crossref_primary_10_1111_all_15252
crossref_primary_10_3389_fimmu_2022_773982
crossref_primary_10_1128_mbio_02979_21
crossref_primary_10_1128_Spectrum_01017_21
crossref_primary_10_1371_journal_ppat_1010260
crossref_primary_10_1126_sciimmunol_abq2427
crossref_primary_10_1016_j_chom_2021_06_016
crossref_primary_10_1021_acs_biochem_1c00139
crossref_primary_10_3389_fmicb_2021_792514
crossref_primary_10_3389_fimmu_2021_687869
crossref_primary_10_1038_s41541_021_00411_7
crossref_primary_10_1016_S0140_6736_21_00675_9
crossref_primary_10_3390_v14061255
crossref_primary_10_26416_FARM_198_1_2021_4353
crossref_primary_10_1016_j_xcrm_2021_100286
crossref_primary_10_3892_etm_2022_11343
crossref_primary_10_1016_j_jconrel_2022_03_032
crossref_primary_10_1016_S0140_6736_21_00370_6
crossref_primary_10_1007_s42399_022_01168_3
crossref_primary_10_1016_j_mgene_2021_100967
crossref_primary_10_1038_s41559_022_01860_6
crossref_primary_10_1002_14651858_CD014945
crossref_primary_10_15252_embj_2021107786
crossref_primary_10_3389_fmed_2021_702066
crossref_primary_10_1021_acs_jmedchem_1c00311
crossref_primary_10_3390_vaccines10060919
crossref_primary_10_7759_cureus_19140
crossref_primary_10_1016_j_isci_2021_103467
crossref_primary_10_1021_acsinfecdis_1c00600
crossref_primary_10_1128_spectrum_01659_21
crossref_primary_10_1038_s41577_021_00657_1
crossref_primary_10_1126_sciadv_abj9815
crossref_primary_10_1007_s10875_022_01354_x
crossref_primary_10_1093_ndt_gfab064
crossref_primary_10_1128_spectrum_01504_21
crossref_primary_10_3389_fimmu_2022_1033770
crossref_primary_10_3934_mbe_2022348
crossref_primary_10_1111_petr_14031
crossref_primary_10_1007_s00705_022_05365_2
crossref_primary_10_1038_s41541_022_00504_x
crossref_primary_10_2217_fvl_2021_0100
crossref_primary_10_3390_v14081766
crossref_primary_10_3389_fimmu_2021_732693
crossref_primary_10_2174_0929867328666210526111318
crossref_primary_10_1126_sciadv_abj5365
crossref_primary_10_1172_jci_insight_150012
crossref_primary_10_1016_j_compbiomed_2023_106618
crossref_primary_10_1093_ve_veab061
crossref_primary_10_3389_fmicb_2021_817200
crossref_primary_10_3390_biom12070964
crossref_primary_10_3390_ijerph19137814
crossref_primary_10_1038_s41467_021_24339_7
crossref_primary_10_3390_jpm12030386
crossref_primary_10_1093_infdis_jiab283
crossref_primary_10_1093_ve_veac026
crossref_primary_10_1002_eji_202149470
crossref_primary_10_1002_14651858_CD014945_pub2
crossref_primary_10_1021_acs_jcim_1c00857
crossref_primary_10_1038_s41467_021_24909_9
crossref_primary_10_1038_s41586_021_03594_0
crossref_primary_10_1016_j_celrep_2022_111831
crossref_primary_10_1016_j_vetmic_2022_109395
crossref_primary_10_1016_j_cmi_2021_05_007
crossref_primary_10_1016_S2468_1253_21_00075_3
crossref_primary_10_1038_s41598_022_07960_4
crossref_primary_10_1016_j_ijmmb_2022_03_009
crossref_primary_10_3389_fpubh_2021_801763
crossref_primary_10_3390_v13091687
crossref_primary_10_1039_D2CP01893D
crossref_primary_10_1093_cid_ciab492
crossref_primary_10_1016_j_addr_2023_114973
crossref_primary_10_1016_j_cell_2021_07_025
crossref_primary_10_1021_acs_chemrestox_1c00129
crossref_primary_10_3390_biomedicines9111740
crossref_primary_10_3390_vaccines9050467
crossref_primary_10_3390_vaccines9101195
crossref_primary_10_1134_S0006297922070021
crossref_primary_10_1016_j_chom_2021_06_009
crossref_primary_10_1007_s10273_021_2894_5
crossref_primary_10_3389_fimmu_2022_786586
crossref_primary_10_3389_fimmu_2022_915034
crossref_primary_10_1126_science_abh1282
Cites_doi 10.1038/s41586-021-03275-y
10.1126/science.1097211
10.1097/INF.0b013e3182367662
10.1101/2020.12.09.20245175
10.1101/2021.01.07.425740
10.1101/2020.12.30.20249034
10.1016/j.chom.2020.06.021
10.1016/j.cell.2020.08.012
10.1126/science.abc4730
10.1371/journal.pone.0025858
10.1056/NEJMoa2034577
ContentType Journal Article
Copyright Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works 2021 American Association for the Advancement of Science
Copyright_xml – notice: Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
– notice: Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
– notice: Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works 2021 American Association for the Advancement of Science
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QF
7QG
7QL
7QP
7QQ
7QR
7SC
7SE
7SN
7SP
7SR
7SS
7T7
7TA
7TB
7TK
7TM
7U5
7U9
8BQ
8FD
C1K
F28
FR3
H8D
H8G
H94
JG9
JQ2
K9.
KR7
L7M
L~C
L~D
M7N
P64
RC3
7X8
5PM
DOI 10.1126/science.abg6105
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Aluminium Industry Abstracts
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Ceramic Abstracts
Chemoreception Abstracts
Computer and Information Systems Abstracts
Corrosion Abstracts
Ecology Abstracts
Electronics & Communications Abstracts
Engineered Materials Abstracts
Entomology Abstracts (Full archive)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Materials Business File
Mechanical & Transportation Engineering Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Solid State and Superconductivity Abstracts
Virology and AIDS Abstracts
METADEX
Technology Research Database
Environmental Sciences and Pollution Management
ANTE: Abstracts in New Technology & Engineering
Engineering Research Database
Aerospace Database
Copper Technical Reference Library
AIDS and Cancer Research Abstracts
Materials Research Database
ProQuest Computer Science Collection
ProQuest Health & Medical Complete (Alumni)
Civil Engineering Abstracts
Advanced Technologies Database with Aerospace
Computer and Information Systems Abstracts – Academic
Computer and Information Systems Abstracts Professional
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Materials Research Database
Technology Research Database
Computer and Information Systems Abstracts – Academic
Mechanical & Transportation Engineering Abstracts
Nucleic Acids Abstracts
ProQuest Computer Science Collection
Computer and Information Systems Abstracts
ProQuest Health & Medical Complete (Alumni)
Materials Business File
Environmental Sciences and Pollution Management
Aerospace Database
Copper Technical Reference Library
Engineered Materials Abstracts
Genetics Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Advanced Technologies Database with Aerospace
ANTE: Abstracts in New Technology & Engineering
Civil Engineering Abstracts
Aluminium Industry Abstracts
Virology and AIDS Abstracts
Electronics & Communications Abstracts
Ceramic Abstracts
Ecology Abstracts
Neurosciences Abstracts
METADEX
Biotechnology and BioEngineering Abstracts
Computer and Information Systems Abstracts Professional
Entomology Abstracts
Animal Behavior Abstracts
Solid State and Superconductivity Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Corrosion Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Materials Research Database
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Biology
Medicine
EISSN 1095-9203
EndPage 1153
ExternalDocumentID PMC7971771
33514629
10_1126_science_abg6105
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United Kingdom
China
United Kingdom--UK
GeographicLocations_xml – name: United Kingdom
– name: China
– name: United Kingdom--UK
GroupedDBID ---
--Z
-DZ
-ET
-~X
.-4
..I
.55
.DC
08G
0R~
0WA
123
18M
2FS
2KS
2WC
2XV
34G
36B
39C
3R3
53G
5RE
66.
6OB
6TJ
7X2
7~K
85S
8F7
AABCJ
AACGO
AAIKC
AAMNW
AANCE
AAWTO
AAYXX
ABCQX
ABDBF
ABDEX
ABDQB
ABEFU
ABIVO
ABJNI
ABOCM
ABPLY
ABPPZ
ABQIJ
ABTLG
ABWJO
ABZEH
ACBEA
ACBEC
ACGFO
ACGFS
ACGOD
ACIWK
ACMJI
ACNCT
ACPRK
ACQOY
ACUHS
ADDRP
ADUKH
ADXHL
AEGBM
AENEX
AETEA
AFBNE
AFFNX
AFHKK
AFQFN
AFRAH
AGNAY
AGSOS
AHMBA
AIDAL
AIDUJ
AJGZS
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
BKF
BLC
C45
CITATION
CS3
DB2
DU5
EBS
EMOBN
F5P
FA8
FEDTE
HZ~
I.T
IAO
IEA
IGS
IH2
IHR
INH
INR
IOF
IOV
IPO
IPY
ISE
JCF
JLS
JSG
JST
K-O
KCC
L7B
LSO
LU7
M0P
MQT
MVM
N9A
NEJ
NHB
O9-
OCB
OFXIZ
OGEVE
OMK
OVD
P-O
P2P
PQQKQ
PZZ
RHI
RXW
SC5
SJN
TAE
TEORI
TN5
TWZ
UBW
UCV
UHB
UKR
UMD
UNMZH
UQL
USG
VVN
WH7
WI4
X7M
XJF
XZL
Y6R
YK4
YKV
YNT
YOJ
YR2
YR5
YRY
YSQ
YV5
YWH
YYP
YZZ
ZCA
ZE2
~02
~G0
~KM
~ZZ
ALIPV
ALSLI
CGR
CUY
CVF
ECM
EIF
NPM
7QF
7QG
7QL
7QP
7QQ
7QR
7SC
7SE
7SN
7SP
7SR
7SS
7T7
7TA
7TB
7TK
7TM
7U5
7U9
8BQ
8FD
C1K
F28
FR3
H8D
H8G
H94
JG9
JQ2
K9.
KR7
L7M
L~C
L~D
M7N
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c515t-cd61357f9e20ed9ba32ed006def0f5297bb3701dfdf1c863b0f92b737984b6f43
ISSN 0036-8075
1095-9203
IngestDate Tue Sep 30 16:33:02 EDT 2025
Sun Sep 28 03:15:47 EDT 2025
Fri Jul 25 10:46:18 EDT 2025
Mon Jul 21 05:47:42 EDT 2025
Wed Oct 01 02:17:19 EDT 2025
Thu Apr 24 23:11:28 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6534
Language English
License https://creativecommons.org/licenses/by/4.0
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c515t-cd61357f9e20ed9ba32ed006def0f5297bb3701dfdf1c863b0f92b737984b6f43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-3389-8414
0000-0003-0671-6360
0000-0001-5450-3218
0000-0003-2989-264X
0000-0002-2222-3227
0000-0003-4561-2273
0000-0003-0363-1564
0000-0002-0623-1497
0000-0002-4030-2500
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7971771
PMID 33514629
PQID 2500551350
PQPubID 1256
PageCount 2
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7971771
proquest_miscellaneous_2483812398
proquest_journals_2500551350
pubmed_primary_33514629
crossref_citationtrail_10_1126_science_abg6105
crossref_primary_10_1126_science_abg6105
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-03-12
PublicationDateYYYYMMDD 2021-03-12
PublicationDate_xml – month: 03
  year: 2021
  text: 2021-03-12
  day: 12
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle Science (American Association for the Advancement of Science)
PublicationTitleAlternate Science
PublicationYear 2021
Publisher The American Association for the Advancement of Science
American Association for the Advancement of Science
Publisher_xml – name: The American Association for the Advancement of Science
– name: American Association for the Advancement of Science
References e_1_3_2_9_2
e_1_3_2_8_2
e_1_3_2_7_2
e_1_3_2_6_2
e_1_3_2_10_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_2_2
33707254 - Science. 2021 Mar 12;371(6534):1103-1104
References_xml – ident: e_1_3_2_12_2
  doi: 10.1038/s41586-021-03275-y
– ident: e_1_3_2_9_2
  doi: 10.1126/science.1097211
– ident: e_1_3_2_3_2
– ident: e_1_3_2_10_2
  doi: 10.1097/INF.0b013e3182367662
– ident: e_1_3_2_8_2
  doi: 10.1101/2020.12.09.20245175
– ident: e_1_3_2_7_2
  doi: 10.1101/2021.01.07.425740
– ident: e_1_3_2_4_2
  doi: 10.1101/2020.12.30.20249034
– ident: e_1_3_2_11_2
  doi: 10.1016/j.chom.2020.06.021
– ident: e_1_3_2_5_2
  doi: 10.1016/j.cell.2020.08.012
– ident: e_1_3_2_6_2
  doi: 10.1126/science.abc4730
– ident: e_1_3_2_13_2
  doi: 10.1371/journal.pone.0025858
– ident: e_1_3_2_2_2
  doi: 10.1056/NEJMoa2034577
– reference: 33707254 - Science. 2021 Mar 12;371(6534):1103-1104
SSID ssj0009593
Score 2.7148905
Snippet The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many...
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to...
Vaccine protects against B1.1.7 variantThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1152
SubjectTerms Adult
Aged
Amino acid sequence
Amino acids
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antisera
China
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - blood
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 vaccines
COVID-19 Vaccines - immunology
Female
Humans
Immunization
Infectivity
Male
Medicine
Microbio
Middle Aged
mRNA
Mutation
Neutralization
Neutralization Tests
Neutralizing
Proteins
Respiratory diseases
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Spike protein
United Kingdom
Vaccines
Young Adult
Title Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
URI https://www.ncbi.nlm.nih.gov/pubmed/33514629
https://www.proquest.com/docview/2500551350
https://www.proquest.com/docview/2483812398
https://pubmed.ncbi.nlm.nih.gov/PMC7971771
Volume 371
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: Academic Search Ultimate (EBSCO)
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1095-9203
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0009593
  issn: 0036-8075
  databaseCode: ABDBF
  dateStart: 19900105
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLZKJyRuEBt_hYGMxMVQlSqxEzu5TAfThLRe0A7tLopjByKmdGqboe2Kd-DZeAGehOPESd2xSgNVitrEcX_O13M-H58fhN56rlS-9CMnAHPj-MpXThgK6rg885UioczrwvMnE3Z86n88C856vV9W1FK1EqPs-ta8kv-RKpwDueos2X-QbDcpnIDnIF84goTheCcZT1RVOyquO943jT9NncP5Z4cMNX_UATnjkQcPPrxYqkrOL4tFtdScczyZeYwIMrxMM7253kY9UHVeZDUPbdr36TYRNoNtlQEw0263x5JxF7YYN8EFbayBuc1yPJxUxbeNFBvbt18smxZVcVk6OuBjUXQgntZ7-772RtbgrL0y3cXvaZvNBiYkHcYj261B6rguz_Z0tpWSG0PVaGdXN5YkLrXVN21auBicssD4Rht9DHyXWLYdXtLb7YbV6VKNUvEFWGWwNpFtWMANy9nFM9YrKcISM0FiJriHdghnjPTRTjx-Pz7aWg3a1Jyysrnaz7BJl_5aA90M5bW40ewRemgWNThuELqLeqrcQ_ebNqdXe2jXCH-JD0yV83ePkdgEL57neA1ebMCLDXixBV4srnALXmzA-_vHzxa2uIYt1rB9gk6PPswOjx3T8MPJgFavnEwCuQx4HiniKhmJlBIlwSxIlbt5QCIuBOWuJ3OZe1nIqHDziAhOeRT6guU-fYr65bxUzxGOmAqDSBIYSv2ckRTWMVnGoiyNfEYlGaBR-7smmamGr5uynCdbZDlAB90NF00hmO1D91tBJUZbLBNYari6mVLgDtCb7jLocr1Bl5ZqXsEYPwQCrStyDtCzRq7de1GdcsNINEB8Q-LdAF0nfvNKWXyt68XziHucey_u_g1eogfr_-Q-6q8WlXoF5HslXhso_wG4tNtR
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neutralization+of+SARS-CoV-2+lineage+B.1.1.7+pseudovirus+by+BNT162b2+vaccine%E2%80%93elicited+human+sera&rft.jtitle=Science+%28American+Association+for+the+Advancement+of+Science%29&rft.au=Muik%2C+Alexander&rft.au=Wallisch%2C+Ann-Kathrin&rft.au=S%C3%A4nger%2C+Bianca&rft.au=Swanson%2C+Kena+A.&rft.date=2021-03-12&rft.issn=0036-8075&rft.eissn=1095-9203&rft.volume=371&rft.issue=6534&rft.spage=1152&rft.epage=1153&rft_id=info:doi/10.1126%2Fscience.abg6105&rft.externalDBID=n%2Fa&rft.externalDocID=10_1126_science_abg6105
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0036-8075&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0036-8075&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0036-8075&client=summon